Objective-Estrogens have multiple effects on vascular physiology and function. In the present study, we look for direct estrogen target genes within junctional proteins. Methods and Results-We use murine endothelial cell lines of brain and heart origin, which express both subtypes of estrogen receptor, ER␣ and ER␤. Treatment of these cells with 17␤-estradiol (E2) led to an increase in transendothelial electric resistance and a most prominent upregulation of the tight junction protein claudin-5 expression. A significant increase of claudin-5 promoter activity, mRNA, and protein levels was detected in cells from both vascular beds. In protein lysates and in immunoreactions on brain sections from ovariectomized E2-treated mice, we noticed an increase in claudin-5 protein and mRNA content. Treatment of cells with a specific ER␤ agonist, diarylpropionitrile, revealed the same effect as E2 stimulation. Moreover, we detected significantly lower claudin-5 mRNA and protein content in ER␤ knockout mice. Conclusions-We describe claudin-5 as a novel estrogen target in vascular endothelium and show in vivo (brain endothelium) and in vitro (brain and heart endothelium) effects of estrogen on claudin-5 levels. The estrogen-induced increase in junctional protein levels may lead to an improvement in vascular structural integrity and barrier function of vascular endothelium. (Arterioscler Thromb Vasc Biol. 2010;30:298-304.)
women are protected from stroke and cardiovascular disease; however, this advantage is lost with menopause. 1 The protective effects of female sex hormones, particularly estrogens, such as the natural endogenous estrogen 17␤estradiol (E2), were confirmed in in vitro experiments and in vivo in animal models. Studies with estrogen receptor (ER) knockout mice confirmed that the vasoprotective effects of estrogen are ER-dependent. 2, 3 Cellular signaling of estrogens is mediated through 2 ER subtypes, ER␣ and ER␤, which are expressed at differing levels in many tissues. 4, 5 The ER activate the transcription of genes directly by binding to estrogen response elements (ERE) in the promoter region of genes. ER-induced transcription may also be indirectly mediated by interaction with Sp1 and AP-1 transcription factors. 6, 7 Although both ER subtypes are expressed in endothelial and smooth muscle cells of blood vessels, most of E2 effects on the vasculature, such re-endothelialization 8 and endothelial nitric oxide production, 9 are ER␣-mediated but not ER␤-mediated.
Intercellular junctions between endothelial cells are important for vascular integrity and function. Claudin-5 is an integral membrane tight junction protein that belongs to a family of transmembrane proteins with 4 transmembrane domains, of which, currently, 24 members have been described. Claudins play an essential role in the control of paracellular ion flux and in the maintenance of cell polarity. 10 Claudin-5 protein was initially considered to be an endothelium-specific member of the claudin protein family. 11 However, in recent years claudin-5 protein expression was demonstrated in numerous other cells and tissues, such as Schwann cells, olfactory epithelium, and in the lateral membranes of cardiomyocytes. [12] [13] [14] Claudin-5 knockout mice are born alive but die within 1 day after birth without any morphological abnormalities. The integrity of the bloodbrain barrier of these mice is severely affected, being selectively permeable to small molecules (Ͻ800-Da). 15 After transient focal ischemia in animal models, tight junction proteins, such as claudin-5 and occludin, are degraded, leading to the opening of the blood-brain barrier, brain edema, and neuronal cell death. 16 Thus, enhanced stability of these structural elements of the vessel lining may underlay the vasoprotective effects observed for estrogens. 17 Therefore, in the present study, we searched for novel estrogen targets among proteins of the junctional complex. Herein, we describe for the first time to our knowledge the tight junction protein claudin-5 as a novel estrogen target in vascular endothelium.
Materials and Methods
Detailed explanation of experimental procedures is provided as supplementary material (available online at http://atvb.ahajournals.org).
Chemicals
The 17␤-estradiol (E2) and propylpyrazole (PPT) were purchased from Sigma. ICI 182.780 and diarylpropionitrile (DPN) were purchased from Biotrend Chemicals AG.
Plasmids
Cloning of the murine claudin-5 promoter (GenBank Accession number EU623469) fragment Ϫ500/ϩ111 in pGL3-basic (Promega) was described previously. 18 
Cell Cultures
Murine microvascular cerebral endothelial cell lines (cEND) and cerebellar endothelial cell lines (cerebEND), as well as the microvascular myocardial endothelial cell line (MyEND), were isolated and immortalized as described previously. 19 -21 
Animal Treatment
The current study was approved by the institutional animal research committee. Twelve-week-old female C57BL/6 mice (Harlan, Eystrup, Germany) were sham-operated or ovariectomized and microosmotic pumps were implanted subcutaneously (model 1004; Alzet). Animals treated with estradiol received mini-pumps filled with cyclodextrin encapsulated estradiol (Sigma) at a dose of 2 g/kg per day. Placebo-treated animals were implanted with micro-osmotic pumps filled with vehicle only (cyclodextrin 23 mg/mL water solution). Five animals per group were analyzed.
Transient Transfection and Reporter Gene Assay
Transient transfection of endothelial cell lines with claudin-5 promoter construct and reporter gene assay were performed as previously described. 18
Western Blot Analysis
Protein extracts from cells or tissue were analyzed by Western blot. Antibodies against claudin-5 (Invitrogen), ␤-actin (Sigma), ER␣, and anti-ER␤ (Santa Cruz Biotechnology) were used. Densitometric analysis using Scion Image Beta 4.02 (Scion Corp) was performed for quantification.
Real-Time Polymerase Chain Reaction
RNA was isolated from tissue or cells and reverse-transcribed. Realtime polymerase chain reaction was performed using the TaqMan PCR Master Mix (Applied Biosystems). Assays for claudin-5, occludin, vascular endothelium-cadherin, and GAPDH were obtained from Applied Biosystems.
Transendothelial Electric Resistance
Transendothelial electric resistance of cell monolayer grown on transwell (0.4 m pores; Falkon) was measured using an assembly containing current-passing and voltage-measuring electrodes (World Precision Instruments Inc). Resistances of blank filters were subtracted from those of filters with cells before final resistances (⍀ ϫ cm 2 ) were calculated. All experiments were repeated at least 3 times.
Immunostaining
Frozen brains from wild-type and ER␤ knockout mice were a kind gift from T. Pelzer (University Würzburg, Department of Medicine, with the permission of Dr K.S. Korach, Receptor Biology Section, NIEHS, NIH, Research Triangle Park, NC). 22 Brain sections were stained with antibodies against platelet/endothelial cell adhesion molecule-1 (1:100; BD Biosciences) and claudin-5 (1:100; Invitrogen). FITC-conjugated/carbocyarin 3-conjugated secondary antibodies were used. The slides were analyzed using a Leica TCSSP confocal microscope. Optical density measurements were performed on 10 randomly selected vessels from 5 sections each using Leica Confocal Software (LCS Lite; Leica Microsystems) to quantify fluorescence.
Analysis and Statistics
Throughout the experiments, averaged values were reported as meansϮSD. Mann-Whitney U-test was performed and PϽ0.05 was considered statistically significant.
Results

Claudin-5 Is a Target Gene for Estrogen Action in Microvascular Endothelium
In a first step, estrogen effects on endothelial barrier properties were tested on microvascular endothelial cells from murine cerebellum (cerebEND) by measuring changes in transendothelial electric resistance in response to treatment with 10 Ϫ8 M E2 for 4, 8, and 24 hours. The cerebEND form a tight monolayer in vitro. 20 Transendothelial electric resistance was increased by 150.6Ϯ20.8% after 4 hours, by 122.26Ϯ18.1% after 8 hours, and by 143.98Ϯ19.9% after 24 hours of treatment ( Figure 1A ). Next, we explored whether and which junctional proteins could be the molecular targets of estrogen action. We analyzed the expression of occludin, vascular endothelium-cadherin, and claudin-5 by real-time polymerase chain reaction ( Figure 1B ). We demonstrated that claudin-5 mRNA was increased up to 2.8Ϯ0.15-fold after 24 hours of treatment with E2. We also observed a small increase in occludin and vascular endothelium-cadherin mRNA expression.
The 2 ER subtypes, ER␣ and ER␤, are expressed differentially in diverse tissues. 23 To control their expression levels in the 3 tested endothelial cell lines, we performed Western blot analysis ( Figure 1C ). We were able to detect strong protein expression of both ER subtypes in all endothelial cell lines tested.
The Claudin-5 Promoter Is Regulated by E2
To examine transcriptional regulation of claudin-5, we previously cloned the murine claudin-5 promoter. 18 Analysis of the promoter sequence with a Genomatix MatInspector (http://www.genomatix.de) and TFSEARCH (http://www.cbrc.jp) revealed several potential transcription factor binding sites. Selected potential transcription factor binding sites are shown in a schematic diagram in Figure 2A . For the present investigation, we failed to identify a conventional ERE, 5Ј-AGGTCANN-NTGACCT-3Ј. 24 However, at positions Ϫ449 to Ϫ463, the murine claudin-5 promoter contains the sequence 5Ј-GGG-TCATGCTGCTAA-3Ј (consensus nucleotides are written in italics). This sequence has the highest homology of the published ERE consensus sequence. We could also detect a putative Sp1 binding site (5Ј-GGGGCAGAGT-3Ј) at positions Ϫ45 to Ϫ55.
The claudin-5 promoter fragment Ϫ500/ϩ111 was cloned into the pGL3-basic vector upstream of the luciferase gene and was then transfected into cEND, cerebEND, and MyEND cell lines. After transfection, the cells were stimulated with 10 Ϫ8 M E2 for 24 hours. Afterward, lysates were prepared to evaluate induction of the luciferase enzyme activity that served as an indicator of promoter transactivation ( Figure 2B ). All cell lines showed an increased promoter activity in response to E2. In MyEND, promoter activity increased 1.36Ϯ0.03 fold, in cerebEND promoter activity increased 1.5Ϯ0.11-fold, and in cEND promoter activity increased 3.7Ϯ0.34-fold.
Claudin-5 mRNA and Protein Induction by E2
To examine whether E2-dependent claudin-5 upregulation could be detected also on the protein and mRNA level, we first performed a dose-response curve in cerebEND cells ( Figure 3A, B) . We treated the cells with 10 Ϫ6 , 10 Ϫ8 , 10 Ϫ10 , and 10 Ϫ12 M of E2 for 24 hours and performed Western blots for claudin-5 and ␤-actin. Claudin-5 protein level was increased in comparison to the untreated sample 3.3Ϯ0.35-fold, 3.0Ϯ0.18-fold, 2.4Ϯ0.17-fold, and 2.2Ϯ0.16-fold in 10 Ϫ6 , 10 Ϫ8 , 10 Ϫ10 , and 10 Ϫ12 M samples, respectively ( Figure 3A) , as determined by densitometric analyses of Western blots. Expression of claudin-5 mRNA increased in comparison to the untreated sample 1.3Ϯ0.16-fold, 1.5Ϯ0.27-fold, 1.3Ϯ0.11-fold, and 1.2Ϯ0.04 fold in 10 Ϫ6 , 10 Ϫ8 , 10 Ϫ10 , and 10 Ϫ12 M samples, respectively ( Figure 3B ). Next, we performed a time-response curve in cerebEND at constant physiological ligand concentration (10 Ϫ8 M). We treated the cerebEND for 6, 12, 24, 48, and 72 hours with E2 ( Figure 3C ). The cells were then lysed and Western blots for claudin-5 and ␤-actin were performed. Claudin-5 protein levels were increased by 3.9Ϯ0.75-fold, 4.07Ϯ0.86-fold, and 5.23Ϯ1.28-fold after 6,12, and 24 hours of E2 treatment, respectively, as determined by densitometric analyses of Western blots. The amount of protein in lysates after 48 hours and 72 hours of stimulation was similar to that of the untreated control. Accordingly, for further experiments we chose the 24-hour stimulation time.
Next, we evaluated whether other endothelial cell lines from different vascular beds, cEND and MyEND, display a similar claudin-5 protein expression pattern as cerebEND in response to E2 ( Figure 3D ). After 24 hours of E2 treatment, claudin-5 protein levels were increased by 2.8Ϯ0.16-fold in cEND and by 2.6Ϯ0.2-fold in MyEND in comparison to untreated controls. We also tested the mRNA expression of claudin-5 after 24 hours of treatment with E2 in all cell lines ( Figure 3E ). Similar to the protein levels, we observed significant increases in claudin-5 mRNA expression, with a 1.81Ϯ0.31-fold increase in cEND, a 1.46Ϯ0.13-fold increase in cerebEND, and a 1.61Ϯ0.3-fold increase in MyEND. The comparatively delayed induction of claudin-5 expression in response to E2 treatment indicated that the effect was caused by genomic action of estrogen. To examine this hypothesis, we included in the treatment solution the nonselective estro- Figure 1 . Claudin-5 is a target for estrogen action in microvascular endothelium. A, E2 administration increases transendothelial electric resistance. CerebEND were seeded on collagen IV coated transwells, grown to confluence in differentiation medium, followed by stimulation with 10 Ϫ8 M E2. Transendothelial electric resistance was measured after 4, 8, and 24 hours. Values are expressed as perecentage over the untreated control, which was set as 100%. B, Effects of E2 on mRNA expression of cell contact proteins. CerebEND were stimulated for 24 hours with or without 10 Ϫ8 M E2, followed by total RNA extraction and quantitative real-time polymerase chain reaction. Occludin, vascular endothelium-cadherin, and claudin-5 expression were normalized to GAPDH and expressed as fold over untreated cells, which was set as 1. C, Estrogen receptors, ER␣ and ER␤, are expressed in endothelial cell lines. Cellular lysates of cEND, cerebEND, MyEND were subjected to Western blot analysis with anti-ER␣ and anti-ER␤ antibodies. *PՅ0.05. gen receptor antagonist ICI 182.780 and examined claudin-5 mRNA levels ( Figure 3E ). The levels of claudin-5 mRNA in the samples treated with E2 /ICI 182.780 were comparable to the untreated control ( Figure 3E ), indicating that estrogen action was blocked when ICI 182.780 was present.
E2 Regulation of Claudin-5 Expression In Vivo in the Mouse
To investigate whether upregulation of claudin-5 expression also takes place in vivo, we sham-operated or ovariectomized mice and randomized them to receive either placebo or estradiol-filled osmotic mini-pumps. After 2 weeks of treatment after the operation, there were significant differences in control and E2-treated animals in weight and size of the uterus (sham-operated: 26.9Ϯ1 mg; ovariectomized: 15.2Ϯ0.3 mg; ovariectomized E2: 106.9Ϯ15 mg; PՅ0.05), which is an estrogen target organ, indicating applicability of the experimental set-up for studying generalized estrogen effects. We analyzed claudin-5 expression in the brains of sham-operated, E2-treated (ovariectomized E2), and placebotreated ovariectomized (control) mice (Figure 4 ). The Western blot analysis showed in sham-operated animals a 0.84Ϯ0.05fold decrease and in ovariectomized E2 brains a 1.53Ϯ0.11-fold increase of claudin-5 protein levels as compared to control ovariectomized brains ( Figure 4A ). Similarly, the mRNA level increased up to 1.6Ϯ0.1-fold in ovariectomized E2 brains, and in sham-operated animals the mRNA level was lowered to 0.92Ϯ0.13-fold as compared to ovariectomized mRNA sample, which was set as 1 ( Figure 4B ).
To further examine claudin-5 regulation in vivo, we performed immunofluorescence stainings with anti-claudin-5 and with anti-platelet/endothelial cell adhesion molecule-1 antibody, the latter serving as an endothelial marker protein, on brain sections from sham-operated, ovariectomized, and ovariectomized E2 mice ( Figure 4C ). Quantification of fluorescence signals revealed that in brains from E2-treated ovariecto-mized mice, claudin-5 staining was enhanced 2.3Ϯ0.55-fold (PϽ0.05) and in sham-operated mice claudin-5 staining was enhanced 1.5Ϯ0.18-fold (PϽ0.05) in comparison to ovariectomized controls, which confirmed claudin-5 upregulation by E2 treatment. Figure 3 . E2 regulation of claudin-5 mRNA and protein expression in endothelial cell lines. A, Dose-response of cerebEND untreated or treated with E2. CerebEND were left untreated or were treated with 10 Ϫ6 , 10 Ϫ8 , 10 Ϫ10 , and 10 Ϫ12 M of E2 for 24 hours, followed by lysis and Western blot with anti-claudin-5 and anti-␤-actin antibody. B, Claudin-5 mRNA dose-response to E2. CerebEND were left untreated or were treated with 10 Ϫ6 , 10 Ϫ8 , 10 Ϫ10 , and 10 Ϫ12 M of E2 for 24 hours, followed by total RNA isolation, reverse transcription, and real-time polymerase chain reaction analysis. Data (meansϮSD) are expressed as fold over untreated control, which was set as 1. C, Time-response of cerebEND untreated or treated with E2. CerebEND were left untreated or were treated for 6, 12, 24, 48, and 72 hours with 10 Ϫ8 M E2, followed by lysis and Western blot with anti-claudin-5 and anti-␤-actin antibody. D, Expression of claudin-5 protein in endothelial cell lines. The cEND and MyEND were treated with or without 10 Ϫ8 M E2 for 24 hours and subjected to Western blot analysis with anti-claudin-5 and anti-␤-actin antibody. E, Claudin-5 mRNA expression in endothelial cell lines after treatment with E2 or E2/ICI 182.780. The cEND, cerebEND, and MyEND were left untreated or were either treated with 10 Ϫ8 M E2 or 10 Ϫ8 M E2/1 mol/L ICI 182.780 for 24 hours, followed by real-time polymerase chain reaction analysis. Data (meansϮSD) are expressed as fold over untreated control, which was set as 1. *PՅ0.05.
Figure 4.
In vivo regulation of claudin-5 in brain of ovariectomized mice. A, Western blot analysis of lysates from brain of sham-operated or ovariectomized mice. Protein lysates from brain of sham-operated or ovariectomized mice untreated or treated with 2 g/kg per day of E2 (ovariectomized E2) were prepared and subjected to Western blot analysis using anticlaudin-5 and anti-␤-actin antibody. B, Claudin-5 mRNA expression in brain from sham-operated, ovariectomized, and ovariectomized E2 mice. Total RNA was isolated from brain tissue of sham-operated, ovariectomized, and ovariectomized E2 mice, reverse-transcribed, and analyzed in real-time polymerase chain reaction. Data (meansϮSD) are expressed as fold over untreated control, which was set as 1. *PՅ0.05. C, Confocal fluorescence microscopy depicting localization of claudin-5 and platelet/endothelial cell adhesion molecule-1 in blood vessels from brain of sham-operated and ovariectomized mice with (ovariectomized E2) and without (ovariectomized) estrogen treatment. Scale bar, 50 m.
E2 Effects on Claudin-5 Expression Are Potentially Mediated Via ER␤
Western blot analysis had revealed the expression of both ER subtypes, ER␣ and ER␤, in cEND, cerebEND, and MyEND ( Figure 1C) . To test which of the ER subtypes could be mediating claudin-5 regulation, we transfected the claudin-5 promoter construct Ϫ500/ϩ111 into cEND and treated the cells with different selective synthetic ER agonists, such as PPT (ER␣ agonist) and DPN (ER␤ agonist), at a concentration of 10 Ϫ8 M ( Figure 5A ). After stimulation, the cells were lysed and promoter activity assay was performed. We observed 1.69Ϯ0.27-fold promoter transactivation in the presence of E2 and 1.7Ϯ0.17-fold promoter transactivation attributable to DPN treatment. There was no transactivation of the claudin-5 promoter in cells stimulated with PPT. Next, we examined the level of claudin-5 expression in brains from ER␤ knockout mice ( Figure 5B-D) . Western blot analysis of brains from wild-type and ER␤ Ϫ/Ϫ mice showed a 0.77Ϯ0.07fold decrease in the level of claudin-5 protein ( Figure 5B) . Similarly, the claudin-5 mRNA expression in ER␤ Ϫ/Ϫ mice was 0.6Ϯ0.12-fold lower as compared to the samples from wild-type animals ( Figure 5C ). Next, we performed immunofluorescence stainings with anti-claudin-5 and with anti-platelet/endothelial cell adhesion molecule-1 antibody on brain sections from wildtype and ER␤ Ϫ/Ϫ mice ( Figure 5D ). Quantification of fluorescence signals revealed that in brains from ER␤ Ϫ/Ϫ mice, claudin-5 staining was 0.6Ϯ0.04-fold (PϽ0.05) lower in comparison to wild-type animals.
Discussion
Protective effects of estrogens on the vasculature have been previously reported. 17 However, the molecular mechanisms of these effects are not completely understood. Intercellular junctions are important structural elements that contribute to the structural and functional integrity of the vessel wall. Therefore, we hypothesized that influence on endothelial junction properties might underlay protective effects of estrogens on the vasculature. So, we designed experiments aiming at providing functional proof of this hypothesis by studying estrogen effects on endothelial permeability and, subsequently, identifying possible estrogen targets among endothelial intercellular junction proteins. To enable comparisons between endothelial cells derived from central nervous system and from non-neural vasculature, we included in the analyses immortalized endothelial cell lines of brain and heart origin, which have been previously proven to posses the typical endothelial properties. 19, 20, 25 Estrogen effects on endothelial barrier functions were initially confirmed by the detection of an E2-mediated increase in transendothelial electric resistance of endothelial monolayers. Additionally, we detected increased expression of claudin-5, occludin, and vascular endothelium-cadherin after treatment with E2. Because E2-effects on claudin-5 expression were the most prominent, we proceeded to analyze in detail the E2-mediated regulation of claudin-5.
The analysis of the murine claudin-5 promoter 18 revealed no canonical ERE in the promoter sequence. 24 However, we identified an imperfect ERE and potential Sp1 transcription factor binding site. The regulation of the claudin-5 promoter could take place either directly by interaction of ER with the DNA via an imperfect ERE or indirectly by interaction with Sp1 protein. In the present study, we report for the first time to our knowledge an increased claudin-5 promoter activity by estradiol treatment of cEND, cerebEND, and MyEND cell lines. The exact molecular mechanism and promoter elements responsible for E2 regulation remain to be determined.
Claudin-5 is expressed ubiquitously in the vascular endothelium. 11 Overexpression of claudin-5 improved bloodbrain barrier function, 26 reduced paracellular cation permeability in Madin-Darby canine kidney II cells, 27 and narrowed paracellular cleft. 28 Here, we demonstrate that with treatment with estrogen, claudin-5 protein levels significantly increased in cEND, cerebEND, and MyEND. The increase was timedependent and dose-dependent, being strongest after 24 hours of 10 Ϫ8 M E2 stimulation. E2 also mediated the induction of claudin-5 expression at the mRNA level, and this effect was blocked by co-administration of the nonselective ER antagonist ICI 182.780.
In humans, ER␣ and ER␤ are expressed in vascular endothelial cells. 29 We also detected expression of both ER subtypes in the murine endothelial cell lines used for this study. The presence of both ER subtypes raised the question of which of the ER could be responsible for the observed claudin-5 regulation. We demonstrate that in the presence of DPN, but not after the stimulation with PPT, claudin-5 Figure 5 . ER␤ is a potential claudin-5 promoter regulator. A, Transactivation of the claudin-5 promoter in response to E2, DPN, and PPT. The cEND were transfected with the Ϫ500/ϩ111 claudin-5 promoter construct. Cells were stimulated with 10 Ϫ8 M E2, 10 Ϫ8 M PPT, or 10 Ϫ8 M DPN for 24 hours, lysed, and subjected to luciferase reporter gene assay. Data (meansϮSD) are expressed as fold over untreated control, which was arbitrarily set as 1. B, Western blot analysis of lysates from brain of ER␤ Ϫ/Ϫ and wild-type mice. Protein lysates from brain of ER␤ Ϫ/Ϫ and wild-type mice were prepared and subjected to Western blot analysis using anti-claudin-5 and anti-␤-actin antibody. C, Claudin-5 mRNA expression in brain from ER␤ Ϫ/Ϫ and wild-type mice. Total RNA was isolated from brain tissue of ER␤ Ϫ/Ϫ and wild-type mice, reverse-transcribed, and analyzed in real-time polymerase chain reaction. Data (meansϮSD) are expressed as fold over sample from wild-type animals, which was set as 1. *PՅ0.05 D, Confocal fluorescence microscopy depicting localization of claudin-5 and platelet/endothelial cell adhesion molecule-1 in blood vessels from brain of ER␤ Ϫ/Ϫ and wild-type mice. Scale bar, 50 m.
promoter activation was increased, indicating that ER␤ might be responsible for claudin-5 regulation. Both ER subtypes have been described to play a role in vascular biology and function. 30 The ER␣ and ER␤ knockout mice differ from each other in several ways. The ER␣ Ϫ/Ϫ mice present uterus atrophy and polycystic ovaries and both male and female mice are sterile, whereas the ER␤ Ϫ/Ϫ mice exhibit different degrees of subfertility. However, this first ER␣ knockout mice study 31 reported residual estradiol binding capacity in uterine tissue of 5% to 10% 32 ; a clear-cut leakage of E2 effect was attributed incorrectly to ER␤. These mice were subsequently shown to present a transcriptional leakage attributable to a non-natural alternative splicing of the ER␣ mRNA, resulting in the expression of a truncated 55-kDa isoform. 33, 34 Such an ER␣ isoform, lacking a major part of the B domain and thus the AF-1 transactivation function, however, was sufficient to mediate the estradiol effect on the endothelial nitric oxide production. 33 In ER␤ Ϫ/Ϫ mice, morphological changes have been demonstrated in prostatic epithelium and in the brain. 22, 35 These abnormalities were not found in 2 other ER␤ Ϫ/Ϫ models. 36, 37 Further abnormalities demonstrated in ER␤ Ϫ/Ϫ were development of hypertension on aging, abnormal vascular and myocardial function, and reduced expression of cell adhesion molecules in various cell types 3, 38, 39 ; however, the present work is the first demonstration, to our knowledge, of a direct endothelial action of E2 through ER␤. Our experiments with the brains from ER␤ Ϫ/Ϫ mice 22 and in an ovariectomized mouse model showed that claudin-5 expression is E2-regulated not only in vitro but also in vivo. We showed a significant increase of claudin-5 mRNA and protein in brain tissue from ovariectomized mice treated with E2 and a significant decrease of claudin-5 mRNA and protein in brains from ER␤ Ϫ/Ϫ mice.
In summary, this study describes a new target gene of estrogen action in vascular endothelium. Using a murine claudin-5 promoter construct and immortalized microvascular endothelial cell lines of brain and heart origin, we show E2-mediated claudin-5 upregulation on promoter, mRNA, and protein levels. Moreover, our observations could be confirmed for brain endothelium in experiments in ovariectomized E2-treated mice and in ER␤ Ϫ/Ϫ mice. Whether a similar regulation of claudin-5 also occurs in other endothelia should be determined in future work.
